Autolus Therapeutics Ownership 2024 | Who Owns Autolus Therapeutics Now?
Institutional Ownership
26.44%
Insider Ownership
18.03%
Retail Ownership
55.53%
Institutional Holders
57.00
Autolus Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 12.27% | 90.76% | 21,346,829 | - | - | 136,192,769 | Mar 31, 2024 |
| BLACKSTONE INC. | 11.78% | 0.53% | 20,485,611 | - | - | 130,698,198 | Mar 31, 2024 |
| DEEP TRACK CAPITAL, LP | 8.78% | 2.79% | 15,272,172 | 3,402,875 | 28.67% | 97,436,457 | Mar 31, 2024 |
| AVORO CAPITAL ADVISORS LLC | 7.10% | 0.92% | 12,345,678 | 12,345,678 | 100.00% | 78,765,426 | Mar 31, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.19% | 0.01% | 10,763,001 | 10,763,001 | 100.00% | 68,667,947 | Mar 31, 2024 |
| FMR LLC | 5.18% | 0.00% | 9,016,390 | 9,014,165 | 405131.01% | 57,524,568 | Mar 31, 2024 |
| TFG ASSET MANAGEMENT GP LTD | 4.33% | 10.88% | 7,525,682 | -474,318 | -5.93% | 48,013,851 | Mar 31, 2024 |
| CORMORANT ASSET MANAGEMENT, LP | 3.80% | 1.85% | 6,616,667 | 1,166,667 | 21.41% | 42,214,335 | Mar 31, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 3.69% | 1.44% | 6,425,803 | -6,185,532 | -49.05% | 40,996,623 | Mar 31, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.16% | 0.00% | 5,488,986 | 2,487,778 | 82.89% | 35,020,000 | Mar 31, 2024 |
| ARMISTICE CAPITAL, LLC | 2.69% | 0.40% | 4,672,000 | 822,000 | 21.35% | 29,807,360 | Mar 31, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 2.66% | 1.24% | 4,623,324 | 876,467 | 23.39% | 29,496,807 | Mar 31, 2024 |
| PERCEPTIVE ADVISORS LLC | 2.49% | 0.48% | 4,330,745 | 2,499,578 | 136.50% | 27,630,153 | Mar 31, 2024 |
| BLACKROCK INC. | 2.33% | 0.00% | 4,055,920 | 2,700,581 | 199.25% | 25,876,769 | Mar 31, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.09% | 0.40% | 3,639,000 | 3,639,000 | 100.00% | 23,216,820 | Mar 31, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.94% | 2.67% | 3,375,000 | 1,824,592 | 117.68% | 21,532,500 | Mar 31, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.84% | 0.04% | 3,200,000 | -625,532 | -16.35% | 20,416,000 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 1.71% | 5.00% | 2,965,721 | 2,514,346 | 557.04% | 18,921,300 | Mar 31, 2024 |
| COMMODORE CAPITAL LP | 1.32% | 0.98% | 2,300,000 | 2,300,000 | 100.00% | 14,674,000 | Mar 31, 2024 |
| PERPETUAL LTD | 1.28% | 0.14% | 2,234,515 | 169,784 | 8.22% | 14,256,206 | Mar 31, 2024 |
Autolus Therapeutics's largest institutional shareholder is SYNCONA PORTFOLIO LTD, holding 12.27% of the company's total share outstanding, currently valued at $136.19M. The top 10 institutional shareholders own together 66.28% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 12.27% | 90.76% | 21,346,829 | - | - | 136,192,769 | Mar 31, 2024 |
| TFG ASSET MANAGEMENT GP LTD | 4.33% | 10.88% | 7,525,682 | -474,318 | -5.93% | 48,013,851 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 1.71% | 5.00% | 2,965,721 | 2,514,346 | 557.04% | 18,921,300 | Mar 31, 2024 |
| DEEP TRACK CAPITAL, LP | 8.78% | 2.79% | 15,272,172 | 3,402,875 | 28.67% | 97,436,457 | Mar 31, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.94% | 2.67% | 3,375,000 | 1,824,592 | 117.68% | 21,532,500 | Mar 31, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 0.80% | 2.30% | 1,390,160 | -468,249 | -25.20% | 8,869,221 | Mar 31, 2024 |
| CORMORANT ASSET MANAGEMENT, LP | 3.80% | 1.85% | 6,616,667 | 1,166,667 | 21.41% | 42,214,335 | Mar 31, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 3.69% | 1.44% | 6,425,803 | -6,185,532 | -49.05% | 40,996,623 | Mar 31, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 2.66% | 1.24% | 4,623,324 | 876,467 | 23.39% | 29,496,807 | Mar 31, 2024 |
| GREAT POINT PARTNERS LLC | 0.67% | 1.16% | 1,166,667 | 1,166,667 | 100.00% | 7,443,335 | Mar 31, 2024 |
| COMMODORE CAPITAL LP | 1.32% | 0.98% | 2,300,000 | 2,300,000 | 100.00% | 14,674,000 | Mar 31, 2024 |
| AVORO CAPITAL ADVISORS LLC | 7.10% | 0.92% | 12,345,678 | 12,345,678 | 100.00% | 78,765,426 | Mar 31, 2024 |
| HIGHVISTA STRATEGIES LLC | 0.15% | 0.59% | 261,324 | 261,324 | 100.00% | 1,667,247 | Mar 31, 2024 |
| BLACKSTONE INC. | 11.78% | 0.53% | 20,485,611 | - | - | 130,698,198 | Mar 31, 2024 |
| PERCEPTIVE ADVISORS LLC | 2.49% | 0.48% | 4,330,745 | 2,499,578 | 136.50% | 27,630,153 | Mar 31, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.09% | 0.40% | 3,639,000 | 3,639,000 | 100.00% | 23,216,820 | Mar 31, 2024 |
| ARMISTICE CAPITAL, LLC | 2.69% | 0.40% | 4,672,000 | 822,000 | 21.35% | 29,807,360 | Mar 31, 2024 |
| HEALTHINVEST PARTNERS AB | 0.06% | 0.37% | 96,345 | - | - | 614,681 | Mar 31, 2024 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.28% | 0.37% | 492,000 | 492,000 | 100.00% | 3,138,960 | Mar 31, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 0.12% | 0.31% | 216,667 | 25,597 | 13.40% | 1,382,335 | Mar 31, 2024 |
The largest Autolus Therapeutics shareholder by % of total assets is SYNCONA PORTFOLIO LTD. The company owns 21.35M shares of Autolus Therapeutics (AUTL), representing 90.76% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AVORO CAPITAL ADVISORS LLC | 7.10% | 0.92% | 12,345,678 | 12,345,678 | 100.00% | 78,765,426 | Mar 31, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.19% | 0.01% | 10,763,001 | 10,763,001 | 100.00% | 68,667,947 | Mar 31, 2024 |
| FMR LLC | 5.18% | 0.00% | 9,016,390 | 9,014,165 | 405131.01% | 57,524,568 | Mar 31, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.09% | 0.40% | 3,639,000 | 3,639,000 | 100.00% | 23,216,820 | Mar 31, 2024 |
| DEEP TRACK CAPITAL, LP | 8.78% | 2.79% | 15,272,172 | 3,402,875 | 28.67% | 97,436,457 | Mar 31, 2024 |
| BLACKROCK INC. | 2.33% | 0.00% | 4,055,920 | 2,700,581 | 199.25% | 25,876,769 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 1.71% | 5.00% | 2,965,721 | 2,514,346 | 557.04% | 18,921,300 | Mar 31, 2024 |
| PERCEPTIVE ADVISORS LLC | 2.49% | 0.48% | 4,330,745 | 2,499,578 | 136.50% | 27,630,153 | Mar 31, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.16% | 0.00% | 5,488,986 | 2,487,778 | 82.89% | 35,020,000 | Mar 31, 2024 |
| COMMODORE CAPITAL LP | 1.32% | 0.98% | 2,300,000 | 2,300,000 | 100.00% | 14,674,000 | Mar 31, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.94% | 2.67% | 3,375,000 | 1,824,592 | 117.68% | 21,532,500 | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.83% | 0.00% | 1,450,791 | 1,450,791 | 100.00% | 9,256,046 | Mar 31, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.20% | 0.11% | 2,090,471 | 1,205,000 | 136.09% | 13,337,205 | Mar 31, 2024 |
| GREAT POINT PARTNERS LLC | 0.67% | 1.16% | 1,166,667 | 1,166,667 | 100.00% | 7,443,335 | Mar 31, 2024 |
| CORMORANT ASSET MANAGEMENT, LP | 3.80% | 1.85% | 6,616,667 | 1,166,667 | 21.41% | 42,214,335 | Mar 31, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 0.59% | 0.17% | 1,032,988 | 1,032,988 | 100.00% | 6,590,463 | Mar 31, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 2.66% | 1.24% | 4,623,324 | 876,467 | 23.39% | 29,496,807 | Mar 31, 2024 |
| ARMISTICE CAPITAL, LLC | 2.69% | 0.40% | 4,672,000 | 822,000 | 21.35% | 29,807,360 | Mar 31, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0.39% | 0.04% | 676,025 | 676,025 | 100.00% | 4,313,040 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.39% | 0.00% | 686,480 | 646,715 | 1626.34% | 4,379,742 | Mar 31, 2024 |
As of Mar 31 2024, Autolus Therapeutics's largest institutional buyer is AVORO CAPITAL ADVISORS LLC. The company purchased 12.35M stocks of AUTL, valued at $78.77M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PARADIGM BIOCAPITAL ADVISORS LP | 3.69% | 1.44% | 6,425,803 | -6,185,532 | -49.05% | 40,996,623 | Mar 31, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.84% | 0.04% | 3,200,000 | -625,532 | -16.35% | 20,416,000 | Mar 31, 2024 |
| TFG ASSET MANAGEMENT GP LTD | 4.33% | 10.88% | 7,525,682 | -474,318 | -5.93% | 48,013,851 | Mar 31, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 0.80% | 2.30% | 1,390,160 | -468,249 | -25.20% | 8,869,221 | Mar 31, 2024 |
| UBS OCONNOR LLC | 0.09% | 0.07% | 155,857 | -382,909 | -71.07% | 994,368 | Mar 31, 2024 |
| IKARIAN CAPITAL, LLC | - | - | - | -262,694 | -100.00% | - | Mar 31, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -251,361 | -100.00% | - | Mar 31, 2024 |
| FRED ALGER MANAGEMENT, LLC | 0.69% | 0.04% | 1,196,876 | -157,455 | -11.63% | 7,636,069 | Mar 31, 2024 |
| CETERA INVESTMENT ADVISERS | - | - | - | -131,500 | -100.00% | - | Mar 31, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.25% | 0.02% | 429,152 | -131,100 | -23.40% | 2,737,989 | Mar 31, 2024 |
| JUMP FINANCIAL, LLC | 0.01% | 0.00% | 25,500 | -128,664 | -83.46% | 162,690 | Mar 31, 2024 |
| WALLEYE TRADING LLC | - | - | - | -44,633 | -100.00% | - | Mar 31, 2024 |
| SIERRA SUMMIT ADVISORS LLC | - | - | - | -42,744 | -100.00% | - | Mar 31, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 0.00% | - | 160 | -31,809 | -99.50% | 1,021 | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | 0.22% | 0.00% | 376,772 | -30,678 | -7.53% | 2,403,806,000 | Mar 31, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -29,822 | -100.00% | - | Mar 31, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | 0.16% | 0.23% | 279,820 | -28,682 | -9.30% | 1,785,000 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.13% | 0.00% | 228,842 | -28,414 | -11.04% | 1,460,012 | Mar 31, 2024 |
| WALLEYE CAPITAL LLC | 0.48% | 0.01% | 828,761 | -21,390 | -2.52% | 5,287,495 | Mar 31, 2024 |
| BELLEVUE GROUP AG | 0.02% | 0.00% | 32,500 | -17,500 | -35.00% | 207,350 | Mar 31, 2024 |
As of Mar 31 2024, Autolus Therapeutics's biggest institutional seller is PARADIGM BIOCAPITAL ADVISORS LP. The company sold -6.19M shares of AUTL, valued at $41.00M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AVORO CAPITAL ADVISORS LLC | 7.10% | 0.92% | 12,345,678 | 12,345,678 | 100.00% | 78,765,426 | Mar 31, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.19% | 0.01% | 10,763,001 | 10,763,001 | 100.00% | 68,667,947 | Mar 31, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.09% | 0.40% | 3,639,000 | 3,639,000 | 100.00% | 23,216,820 | Mar 31, 2024 |
| COMMODORE CAPITAL LP | 1.32% | 0.98% | 2,300,000 | 2,300,000 | 100.00% | 14,674,000 | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.83% | 0.00% | 1,450,791 | 1,450,791 | 100.00% | 9,256,046 | Mar 31, 2024 |
| GREAT POINT PARTNERS LLC | 0.67% | 1.16% | 1,166,667 | 1,166,667 | 100.00% | 7,443,335 | Mar 31, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 0.59% | 0.17% | 1,032,988 | 1,032,988 | 100.00% | 6,590,463 | Mar 31, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0.39% | 0.04% | 676,025 | 676,025 | 100.00% | 4,313,040 | Mar 31, 2024 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.29% | 0.01% | 512,847 | 512,847 | 100.00% | 3,271,964 | Mar 31, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.29% | 0.30% | 500,000 | 500,000 | 100.00% | 3,190,000 | Mar 31, 2024 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.28% | 0.37% | 492,000 | 492,000 | 100.00% | 3,138,960 | Mar 31, 2024 |
| NOMURA ASSET MANAGEMENT CO LTD | 0.22% | 0.01% | 384,796 | 384,796 | 100.00% | 2,454,998 | Mar 31, 2024 |
| HIGHVISTA STRATEGIES LLC | 0.15% | 0.59% | 261,324 | 261,324 | 100.00% | 1,667,247 | Mar 31, 2024 |
| STEMPOINT CAPITAL LP | 0.14% | 0.02% | 250,000 | 250,000 | 100.00% | 68,750 | Mar 31, 2024 |
| VOYA INVESTMENT MANAGEMENT LLC | 0.12% | 0.00% | 205,225 | 205,225 | 100.00% | 1,309,336 | Mar 31, 2024 |
| OCTAGON CAPITAL ADVISORS LP | 0.10% | 0.13% | 176,000 | 176,000 | 100.00% | 1,122,880 | Mar 31, 2024 |
| CETERA ADVISORS LLC | 0.08% | 0.01% | 131,500 | 131,500 | 100.00% | 838,970 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.05% | 0.00% | 83,100 | 83,100 | 100.00% | 530,178 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.04% | 0.00% | 71,219 | 71,219 | 100.00% | 454,377 | Mar 31, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 0.04% | 0.00% | 60,928 | 60,928 | 100.00% | 388,721 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.03% | 0.00% | 60,000 | 60,000 | 100.00% | 382,800 | Mar 31, 2024 |
| ALLIANZ ASSET MANAGEMENT GMBH | 0.02% | 0.00% | 38,700 | 38,700 | 100.00% | 246,906 | Mar 31, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.02% | 0.00% | 37,300 | 37,300 | 100.00% | 237,974 | Mar 31, 2024 |
| SG AMERICAS SECURITIES, LLC | 0.01% | 0.00% | 19,853 | 19,853 | 100.00% | 127,000 | Mar 31, 2024 |
| AMERIPRISE FINANCIAL INC | 0.01% | - | 16,692 | 16,692 | 100.00% | 106,495 | Mar 31, 2024 |
| BAYESIAN CAPITAL MANAGEMENT, LP | 0.01% | 0.01% | 15,600 | 15,600 | 100.00% | 99,528 | Mar 31, 2024 |
| FRANKLIN RESOURCES INC | 0.01% | - | 10,000 | 10,000 | 100.00% | 63,800 | Mar 31, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.00% | 0.00% | 7,370 | 7,370 | 100.00% | 47,000 | Mar 31, 2024 |
| AQUATIC CAPITAL MANAGEMENT LLC | 0.00% | 0.00% | 3,100 | 3,100 | 100.00% | 19,778 | Mar 31, 2024 |
| ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 0.00% | 0.00% | 2,633 | 2,633 | 100.00% | 16,799 | Mar 31, 2024 |
Autolus Therapeutics's largest new institutional shareholder by number of shares is AVORO CAPITAL ADVISORS LLC, purchased 12.35M shares, valued at $78.77M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| IKARIAN CAPITAL, LLC | - | - | - | -262,694 | -100.00% | - | Mar 31, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -251,361 | -100.00% | - | Mar 31, 2024 |
| CETERA INVESTMENT ADVISERS | - | - | - | -131,500 | -100.00% | - | Mar 31, 2024 |
| WALLEYE TRADING LLC | - | - | - | -44,633 | -100.00% | - | Mar 31, 2024 |
| SIERRA SUMMIT ADVISORS LLC | - | - | - | -42,744 | -100.00% | - | Mar 31, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | - | - | - | -29,822 | -100.00% | - | Mar 31, 2024 |
| PARKSIDE FINANCIAL BANK & TRUST | - | - | - | -200 | -100.00% | - | Mar 31, 2024 |
Autolus Therapeutics's largest sold out institutional shareholder by shares sold is IKARIAN CAPITAL, LLC, sold -0.26M shares, valued at -, as of undefined.
Autolus Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Alger ETF Trust | 6.46% | 45,861 | 45,861 | - | Dec 31, 2023 |
| ALGER INSTITUTIONAL FUNDS | 0.49% | 126,568 | 126,568 | - | Jan 31, 2024 |
| ALGER PORTFOLIOS | 0.43% | 159,816 | 159,816 | - | Dec 31, 2023 |
| ALGER FUNDS | 0.34% | 323,215 | 323,215 | - | Jan 31, 2024 |
| ALGER FUNDS II | 0.31% | 69,091 | 69,091 | - | Jan 31, 2024 |
| BlackRock Health Sciences Trust II | 0.17% | 462,111 | 462,111 | - | Dec 31, 2023 |
| FIDELITY ADVISOR SERIES VII | 0.12% | 996,000 | - | - | Jan 31, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.07% | 1,099,247 | 571,442 | 108.27% | Dec 31, 2023 |
| BNY MELLON VARIABLE INVESTMENT FUND | 0.05% | 12,322 | 12,322 | - | Mar 31, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.05% | 230,858 | - | - | Dec 31, 2023 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.03% | 101,096 | - | - | Dec 31, 2023 |
| ETFis Series Trust I | 0.02% | 27,536 | - | - | Jan 31, 2024 |
| Harbor ETF Trust | 0.01% | 64,128 | -30,988 | -32.58% | Jan 31, 2024 |
| ALPS ETF Trust | 0.01% | 122,678 | - | - | Feb 29, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 618,833 | 238,648 | 62.77% | Feb 29, 2024 |
| SMALLCAP WORLD FUND INC | 0.01% | 625,000 | - | - | Dec 31, 2023 |
| FORUM FUNDS II | 0.01% | 6,402 | - | - | Jan 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.01% | 11,178 | - | - | Dec 31, 2023 |
| HARBOR FUNDS | 0.01% | 150,589 | -80,172 | -34.74% | Jan 31, 2024 |
| Destra Investment Trust | 0.00% | 6,606 | - | - | Dec 31, 2023 |
| JOHCM Funds Trust | 0.00% | 43,079 | -10,709 | -19.91% | Dec 29, 2023 |
| ETF Series Solutions | 0.00% | 57,474 | 9,211 | 19.09% | Feb 29, 2024 |
| T. Rowe Price Equity Funds, Inc. | 0.00% | 53,650 | - | - | Dec 31, 2023 |
| VICTORY PORTFOLIOS | 0.00% | 78,200 | 23,920 | 44.07% | Dec 31, 2023 |
| BlackRock ETF Trust | 0.00% | 949 | 949 | - | Jan 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.00% | 3,351 | - | - | Feb 29, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 44,108 | 44,108 | - | Feb 29, 2024 |
| RBB FUND, INC. | 0.00% | 48,359 | 48,359 | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 86,256 | - | - | Feb 29, 2024 |
| Fidelity Rutland Square Trust II | 0.00% | 398,650 | 398,650 | - | Feb 29, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 52,387 | - | - | Dec 31, 2023 |
| Weiss Strategic Interval Fund | 0.00% | 907 | 907 | - | Sep 30, 2022 |
| BLACKROCK FUNDS | 0.00% | 889,962 | 889,962 | - | Feb 29, 2024 |
| VALIC Co I | 0.00% | 36,451 | 21,983 | 151.94% | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 810,276 | - | - | Feb 29, 2024 |
| PROSHARES TRUST | 0.00% | 10,501 | 5,635 | 115.80% | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 12,642 | - | - | Jan 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 11,490 | 1,054 | 10.10% | Feb 29, 2024 |
| LoCorr Investment Trust | 0.00% | 550 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 9,662 | 5,886 | 155.88% | Dec 31, 2023 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 13,812 | 7,386 | 114.94% | Dec 31, 2023 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 5,472 | 3,326 | 154.99% | Dec 31, 2023 |
| John Hancock Funds II | 0.00% | 38,774 | 38,774 | - | Feb 29, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 200 | - | - | Dec 31, 2023 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 887 | - | - | Dec 31, 2023 |
Autolus Therapeutics's largest mutual fund holder by % of total assets is "Alger ETF Trust", owning 45.86K shares, compromising 6.46% of its total assets.
Autolus Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 57 | -40.63% |
| 31 Dec, 23 | 96 | 41.18% |
| 30 Sep, 23 | 68 | - |
| 30 Jun, 23 | 68 | 6.25% |
| 31 Mar, 23 | 64 | -7.25% |
| 31 Dec, 22 | 69 | 11.29% |
| 30 Sep, 22 | 62 | - |
| 30 Jun, 22 | 62 | - |
| 31 Mar, 22 | 62 | -8.82% |
| 31 Dec, 21 | 68 | 17.24% |
| 30 Sep, 21 | 58 | -7.94% |
| 30 Jun, 21 | 63 | 3.28% |
| 31 Mar, 21 | 61 | 29.79% |
| 31 Dec, 20 | 47 | 2.17% |
| 30 Sep, 20 | 46 | -8.00% |
| 30 Jun, 20 | 50 | -1.96% |
| 31 Mar, 20 | 51 | -7.27% |
| 31 Dec, 19 | 55 | 25.00% |
| 30 Sep, 19 | 44 | -6.38% |
| 30 Jun, 19 | 47 | 30.56% |
| 31 Mar, 19 | 36 | -5.26% |
| 31 Dec, 18 | 38 | -2.56% |
| 30 Sep, 18 | 39 | -22.00% |
| 30 Jun, 18 | 50 | - |
As of 31 Mar 24, 57 institutions are holding Autolus Therapeutics's shares, representing a decrease of -40.63% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 45,993,275 | -60.21% |
| 31 Dec, 23 | 115,589,950 | 4.58% |
| 30 Sep, 23 | 110,531,704 | 1.28% |
| 30 Jun, 23 | 109,136,054 | 3.22% |
| 31 Mar, 23 | 105,728,701 | -0.85% |
| 31 Dec, 22 | 106,639,678 | 116.59% |
| 30 Sep, 22 | 49,235,696 | -2.88% |
| 30 Jun, 22 | 50,695,618 | -4.42% |
| 31 Mar, 22 | 53,040,341 | 1.49% |
| 31 Dec, 21 | 52,261,223 | 110.25% |
| 30 Sep, 21 | 24,856,956 | -1.34% |
| 30 Jun, 21 | 25,195,749 | 12.47% |
| 31 Mar, 21 | 22,402,923 | 77.86% |
| 31 Dec, 20 | 12,596,157 | -0.38% |
| 30 Sep, 20 | 12,644,809 | -11.75% |
| 30 Jun, 20 | 14,328,878 | -10.32% |
| 31 Mar, 20 | 15,977,842 | 19.02% |
| 31 Dec, 19 | 13,423,962 | -0.16% |
| 30 Sep, 19 | 13,445,027 | -37.26% |
| 30 Jun, 19 | 21,429,033 | 18.24% |
| 31 Mar, 19 | 18,123,353 | 6.68% |
| 31 Dec, 18 | 16,988,891 | -4.84% |
| 30 Sep, 18 | 17,853,091 | 98.15% |
| 30 Jun, 18 | 9,010,057 | - |
Autolus Therapeutics (AUTL) has 45.99M shares outstanding as of 31 Mar 24, down -60.21% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 26.44% | 0.60% |
| 31 Dec, 23 | 66.44% | 1.64% |
| 30 Sep, 23 | 63.57% | 1.61% |
| 30 Jun, 23 | 62.78% | 1.70% |
| 31 Mar, 23 | 60.82% | 0.48% |
| 31 Dec, 22 | 112.26% | 3.86% |
| 30 Sep, 22 | 53.96% | 1.74% |
| 30 Jun, 22 | 55.75% | 1.64% |
| 31 Mar, 22 | 58.34% | 1.14% |
| 31 Dec, 21 | 71.69% | 6.17% |
| 30 Sep, 21 | 34.10% | 2.69% |
| 30 Jun, 21 | 35.57% | 2.76% |
| 31 Mar, 21 | 35.87% | 6.01% |
| 31 Dec, 20 | 24.43% | 4.15% |
| 30 Sep, 20 | 24.27% | 3.20% |
| 30 Jun, 20 | 27.53% | 2.68% |
| 31 Mar, 20 | 32.05% | 4.42% |
| 31 Dec, 19 | 26.92% | 2.95% |
| 30 Sep, 19 | 30.21% | 1.25% |
| 30 Jun, 19 | 49.14% | 2.33% |
| 31 Mar, 19 | 45.92% | 2.47% |
| 31 Dec, 18 | 43.16% | 1.35% |
| 30 Sep, 18 | 56.57% | 6.94% |
| 30 Jun, 18 | 28.55% | - |
As of 31 Mar 24, Autolus Therapeutics is held by 26.44% institutional shareholders, representing a 0.60% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 27 | -48.08% |
| 31 Dec, 23 | 52 | 126.09% |
| 30 Sep, 23 | 23 | -30.30% |
| 30 Jun, 23 | 33 | 17.86% |
| 31 Mar, 23 | 28 | -28.21% |
| 31 Dec, 22 | 39 | 95.00% |
| 30 Sep, 22 | 20 | -20.00% |
| 30 Jun, 22 | 25 | -3.85% |
| 31 Mar, 22 | 26 | -36.59% |
| 31 Dec, 21 | 41 | 36.67% |
| 30 Sep, 21 | 30 | -30.23% |
| 30 Jun, 21 | 43 | 4.88% |
| 31 Mar, 21 | 41 | 95.24% |
| 31 Dec, 20 | 21 | 40.00% |
| 30 Sep, 20 | 15 | -25.00% |
| 30 Jun, 20 | 20 | -33.33% |
| 31 Mar, 20 | 30 | 3.45% |
| 31 Dec, 19 | 29 | 31.82% |
| 30 Sep, 19 | 22 | -40.54% |
| 30 Jun, 19 | 37 | 164.29% |
| 31 Mar, 19 | 14 | -17.65% |
| 31 Dec, 18 | 17 | -5.56% |
| 30 Sep, 18 | 18 | -64.00% |
| 30 Jun, 18 | 50 | - |
27 institutional shareholders have increased their position in AUTL stock as of 31 Mar 24 compared to 52 in the previous quarter (a -48.08% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 13 | -35.00% |
| 31 Dec, 23 | 20 | -16.67% |
| 30 Sep, 23 | 24 | 71.43% |
| 30 Jun, 23 | 14 | 27.27% |
| 31 Mar, 23 | 11 | -15.38% |
| 31 Dec, 22 | 13 | -35.00% |
| 30 Sep, 22 | 20 | 11.11% |
| 30 Jun, 22 | 18 | -28.00% |
| 31 Mar, 22 | 25 | 66.67% |
| 31 Dec, 21 | 15 | 7.14% |
| 30 Sep, 21 | 14 | 27.27% |
| 30 Jun, 21 | 11 | 10.00% |
| 31 Mar, 21 | 10 | -41.18% |
| 31 Dec, 20 | 17 | -5.56% |
| 30 Sep, 20 | 18 | -14.29% |
| 30 Jun, 20 | 21 | 110.00% |
| 31 Mar, 20 | 10 | -28.57% |
| 31 Dec, 19 | 14 | 7.69% |
| 30 Sep, 19 | 13 | 116.67% |
| 30 Jun, 19 | 6 | -57.14% |
| 31 Mar, 19 | 14 | -22.22% |
| 31 Dec, 18 | 18 | 28.57% |
| 30 Sep, 18 | 14 | - |
| 30 Jun, 18 | - | - |
13 institutional shareholders have reduced their position in AUTL stock as of 31 Mar 24 compared to 20 in the previous quarter (a -35.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 57 | -40.63% | 45,993,275 | -60.21% | 26.44% | 0.60% | 27 | -48.08% | 13 | -35.00% |
| 31 Dec, 23 | 96 | 41.18% | 115,589,950 | 4.58% | 66.44% | 1.64% | 52 | 126.09% | 20 | -16.67% |
| 30 Sep, 23 | 68 | - | 110,531,704 | 1.28% | 63.57% | 1.61% | 23 | -30.30% | 24 | 71.43% |
| 30 Jun, 23 | 68 | 6.25% | 109,136,054 | 3.22% | 62.78% | 1.70% | 33 | 17.86% | 14 | 27.27% |
| 31 Mar, 23 | 64 | -7.25% | 105,728,701 | -0.85% | 60.82% | 0.48% | 28 | -28.21% | 11 | -15.38% |
| 31 Dec, 22 | 69 | 11.29% | 106,639,678 | 116.59% | 112.26% | 3.86% | 39 | 95.00% | 13 | -35.00% |
| 30 Sep, 22 | 62 | - | 49,235,696 | -2.88% | 53.96% | 1.74% | 20 | -20.00% | 20 | 11.11% |
| 30 Jun, 22 | 62 | - | 50,695,618 | -4.42% | 55.75% | 1.64% | 25 | -3.85% | 18 | -28.00% |
| 31 Mar, 22 | 62 | -8.82% | 53,040,341 | 1.49% | 58.34% | 1.14% | 26 | -36.59% | 25 | 66.67% |
| 31 Dec, 21 | 68 | 17.24% | 52,261,223 | 110.25% | 71.69% | 6.17% | 41 | 36.67% | 15 | 7.14% |
| 30 Sep, 21 | 58 | -7.94% | 24,856,956 | -1.34% | 34.10% | 2.69% | 30 | -30.23% | 14 | 27.27% |
| 30 Jun, 21 | 63 | 3.28% | 25,195,749 | 12.47% | 35.57% | 2.76% | 43 | 4.88% | 11 | 10.00% |
| 31 Mar, 21 | 61 | 29.79% | 22,402,923 | 77.86% | 35.87% | 6.01% | 41 | 95.24% | 10 | -41.18% |
| 31 Dec, 20 | 47 | 2.17% | 12,596,157 | -0.38% | 24.43% | 4.15% | 21 | 40.00% | 17 | -5.56% |
| 30 Sep, 20 | 46 | -8.00% | 12,644,809 | -11.75% | 24.27% | 3.20% | 15 | -25.00% | 18 | -14.29% |
| 30 Jun, 20 | 50 | -1.96% | 14,328,878 | -10.32% | 27.53% | 2.68% | 20 | -33.33% | 21 | 110.00% |
| 31 Mar, 20 | 51 | -7.27% | 15,977,842 | 19.02% | 32.05% | 4.42% | 30 | 3.45% | 10 | -28.57% |
| 31 Dec, 19 | 55 | 25.00% | 13,423,962 | -0.16% | 26.92% | 2.95% | 29 | 31.82% | 14 | 7.69% |
| 30 Sep, 19 | 44 | -6.38% | 13,445,027 | -37.26% | 30.21% | 1.25% | 22 | -40.54% | 13 | 116.67% |
| 30 Jun, 19 | 47 | 30.56% | 21,429,033 | 18.24% | 49.14% | 2.33% | 37 | 164.29% | 6 | -57.14% |
| 31 Mar, 19 | 36 | -5.26% | 18,123,353 | 6.68% | 45.92% | 2.47% | 14 | -17.65% | 14 | -22.22% |
| 31 Dec, 18 | 38 | -2.56% | 16,988,891 | -4.84% | 43.16% | 1.35% | 17 | -5.56% | 18 | 28.57% |
| 30 Sep, 18 | 39 | -22.00% | 17,853,091 | 98.15% | 56.57% | 6.94% | 18 | -64.00% | 14 | - |
| 30 Jun, 18 | 50 | - | 9,010,057 | - | 28.55% | - | 50 | - | - | - |
Autolus Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| ANEB | Anebulo Pharmaceuticals, Inc. |
| RZLT | Rezolute, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| XFOR | X4 Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
| IKNA | Ikena Oncology, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CELC | Celcuity Inc. |
AUTL Ownership FAQ
Who Owns Autolus Therapeutics?
Autolus Therapeutics is owned by institutional shareholders (26.44%), insiders (18.03%), and public (55.53%). The largest institutional shareholder of Autolus Therapeutics is SYNCONA PORTFOLIO LTD (12.27% of total shares) and the top mutual fund owner is Alger ETF Trust (6.46% of total shares).
Who are the major institutional shareholders of Autolus Therapeutics?
Autolus Therapeutics's major institutional shareholders are SYNCONA PORTFOLIO LTD, BLACKSTONE INC., DEEP TRACK CAPITAL, LP, AVORO CAPITAL ADVISORS LLC, and WELLINGTON MANAGEMENT GROUP LLP. The top five shareholders own together 46.12% of the company's share outstanding.
How many Autolus Therapeutics shareholders are there?
As of Mar 2024, there are 57 institutional shareholders of Autolus Therapeutics.
What percentage of Autolus Therapeutics is owned by SYNCONA PORTFOLIO LTD?
SYNCONA PORTFOLIO LTD owns 21.35M shares of Autolus Therapeutics, representing 12.27% of the company's total shares outstanding, valued at $136.19M (as of Mar 2024).
What percentage of Autolus Therapeutics is owned by BLACKSTONE INC?
As of Mar 2024, BLACKSTONE INC holds 20.49M shares of Autolus Therapeutics (AUTL), compromising 11.78% of the company, valued at $130.7M.
What percentage of Autolus Therapeutics is owned by DEEP TRACK CAPITAL, LP?
DEEP TRACK CAPITAL, LP is the third largest holder of Autolus Therapeutics. The company owns 15.27M of the company's shares outstanding (worth $97.44M).